Four New Biotechs Launch to Combat MD, NASH, Parkinson's and More

There’s plenty of money on the move as venture capital firms and investors look to the future of biotech. Read on for today’s top Series A rounds.

Vita Therapeutics – The Baltimore, Maryland-based company announced an oversubscribed Series A financing worth $32 million. It was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures.